Savient Pharmaceuticals Inc. plans to sell its drug portfolio, including the gout treatment Krystexxa, to Crealta Pharmaceuticals LLC for $120.4 million, pending bankruptcy court approval, the Associated Press reported yesterday. Savient, based in Bridgewater, N.J., filed for chapter 11 protection in October. It said yesterday that the deal with Crealta was reached following bankruptcy court-approved auction. The companies will seek required court approval for the sale on Friday.
